Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Media ▼Online-CME News ▼Meeting Reports Slides ▼About

ACC 2020 ▼AHA 2020 ▼Covid-19 ▼Diabetes & CVD ▼ESC 2020 ▼HF Practical Tutorials ▼Kidney disease & CVD ▼

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016

Share this page with your colleagues and friends:

Continue reading:

4 Things a cardiologist should know about triglycerides

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

5 Things a cardiologist needs to know about GLP-1RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Similar risk of NACE when comparing two P2Y12 inhibitors in patients with ACS after PCI

Literature - Dec. 15, 2020 - You SC, et al. - JAMA. 2020

Comparison of two P2Y12 inhibitors in ACS patients with diabetes

Literature - Nov. 9, 2020 - Ndrepepa G, et al. - JACC Cardiovasc Interv 2020

Total CV events lowered by PCSK9i-induced Lp(a) reduction in ACS patients

Literature - Nov. 6, 2020 - Szarek M, et al. - Eur Heart J. 2020

Atherosclerosis

People aged 70-100 years with elevated LDL-c are at high risk of MI and ASCVD

Literature - Jan. 21, 2021 - Mortensen MB & Nordestgaard BG., - Lancet. 2020

Silent CAD present in 4 out of 10 Swedish individuals

News - Nov. 14, 2020

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Atrial fibrillation

An overview of the global burden of CVD and risk factors from 1990 to 2019

Literature - Jan. 14, 2021 - Roth GA, et al. - J Am Coll Cardiol. 2020

NOAC non-inferior to warfarin in AF patients with bioprosthetic mitral valve

News - Nov. 15, 2020

Omega-3 fatty acids and/or vitamin D3 supplementation do not reduce incident AF

News - Nov. 14, 2020

BET Inhibition

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Primary endpoint not met for BET inhibitor in phase 3 trial

News - Sep. 30, 2019

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

Covid-19

High incidence of thrombotic complications in hospitalized COVID-19 patients in the first and second wave

Literature - Jan. 25, 2021 - Kaptein FHJ et al., - Thrombosis Research 2020.

Patients with HF hospitalized with COVID-19 at high risk for poor outcomes

Literature - Jan. 19, 2021 - Alvarez-Garcia J, et al. - J Am Coll Cardiol. 2020

Endothelial injury and dysfunction in COVID-19

Literature - Jan. 19, 2021 - Evans PC et al., - Cardiovasc Res. 2020

Covid-19, ACE2, RAASi

COVID-19, ACE2 and RAAS inhibition

Online-CME - This course consists of 3 parts.

COVID-19, ACE2 and RAAS inhibition

Lecture - Apr. 29, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD

CV Inflammation

Anti-inflammatory treatment within 3 days after MI improves CV outcomes

Literature - Jan. 25, 2021 - Bouabdallaoui N, et al. - Eur Heart J. 2020

Endothelial injury and dysfunction in COVID-19

Literature - Jan. 19, 2021 - Evans PC et al., - Cardiovasc Res. 2020

COVID-19 and risk of HFpEF

News - Nov. 3, 2020

CVRM

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

Persons with NAFLD are not automatically at high risk of acute MI or stroke

Literature - Nov. 4, 2019 - Alexander M et al, - BMJ 2019

Diabetes

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD

E-learning Reducing CV risk in diabetes

Online-CME - This course consists of 3 parts.

E-learning The evolving role of triglyceride-rich lipoproteins

Online-CME - This course consists of 3 parts.

Diabetes & CVD

2021 Update to the 2017 ACC ECDP for optimization HFrEF treatment

News - Jan. 19, 2021

E-learning 5 Things a cardiologist needs to know about GLP-1 RA

Online-CME - This course consists of 5 lectures.

SGLT2 inhibitor reduces total burden of CVD in patients with T2DM and ASCVD

Literature - Jan. 7, 2021 - McGuire DK, et al. - Lancet Diabetes Endocrinol 202

Epigenetics in CVD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

BET inhibitor therapy did not meet primary endpoint of reducing MACE in post-ACS patients with T2DM

News - Nov. 17, 2019

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

ESC Diabetes guidelines 2019

Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale

Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

New ESC/EASD Guidelines on diabetes no longer regard metformin as first-line therapy

News - Sep. 3, 2019

ESC/EAS Guidelines dyslipidaemias 2019

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Slides: LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

Slides (presentation) - Sep. 9, 2019 - ESC Paris, France - Prof. Brian A. Ference, M.D, University of Cambridge, United Kingdom - CME symposium held during ESC 2019

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

Familial Hypercholesterolemia

Angiopoietin-like 3 antibody halves LDL-c levels in patients with refractory hypercholesterolemia

Literature - Jan. 18, 2021 - Rosenson RS, et al. - N Engl J Med. 2020

PCSK9i siRNA therapy for lowering LDL-c levels approved by EC

News - Dec. 14, 2020

PCSK9 siRNA recommended by CHMP for EU approval

News - Oct. 28, 2020

German videos

Möglichkeiten in der Lipidtherapie die unabhängig vom LDL-c das residuale Risiko reduzieren

Residuales Risiko: Die Rolle der Hypertriglyceridämie

GLP-1 RA & CVD

E-learning 5 Things a cardiologist needs to know about GLP-1 RA

Online-CME - This course consists of 5 lectures.

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD

How do GLP-1RAs work?

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD

Heart Failure

2021 Update to the 2017 ACC ECDP for optimization HFrEF treatment

News - Jan. 19, 2021

Patients with HF hospitalized with COVID-19 at high risk for poor outcomes

Literature - Jan. 19, 2021 - Alvarez-Garcia J, et al. - J Am Coll Cardiol. 2020

Early increase ANP after ARNI initiation associated with reverse cardiac remodeling in HFrEF

Literature - Jan. 19, 2021 - Murphy SP, et al. - JACC Heart Fail. 2020

HFpEF: The essentials to know

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

Hypertension

An overview of the global burden of CVD and risk factors from 1990 to 2019

Literature - Jan. 14, 2021 - Roth GA, et al. - J Am Coll Cardiol. 2020

Causal mechanism of age-related hypertension endotype identified

Literature - Dec. 8, 2020 - Elbatreek MH, et al. - PLoS Biol 2020

Moderate and heavy alcohol consumption associated with hypertension

Literature - Sep. 28, 2020 - Mayl JJ et al. - J Am Heart Assoc. 2020

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Kidney disease & CVD

Nonsteroidal MRA reduces kidney and CV risks in patients with CKD and T2DM with or without CVD

News - Nov. 24, 2020

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

Dual SGLT1 and SGLT2 inhibitor reduces CV outcomes in diabetes patients in two settings

News - Nov. 19, 2020

LDL-c Key Lessons

Key lessons on LDL-c and CV risk

LDL-c Key lessons

Screening for familial hypercholesterolemia after ACS pays off

LDL-c Key Lessons

LDL-c lowering treatment impacts disease progression before clinical manifestation

LDL-c Key Lessons

Lipids

People aged 70-100 years with elevated LDL-c are at high risk of MI and ASCVD

Literature - Jan. 21, 2021 - Mortensen MB & Nordestgaard BG., - Lancet. 2020

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

E-learning The evolving role of triglyceride-rich lipoproteins

Online-CME - This course consists of 3 parts.

Lp(a)

E-learning Lp(a), a new lipid frontier in CV risk management

Online-CME - This course consists of 3 parts.

Total CV events lowered by PCSK9i-induced Lp(a) reduction in ACS patients

Literature - Nov. 6, 2020 - Szarek M, et al. - Eur Heart J. 2020

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD

PCSK9

E-learning PCSK9i & LDL-c: Guidelines, Practice and Innovation

Online-CME - This course consists of 3 parts.

E-learning Lp(a), a new lipid frontier in CV risk management

Online-CME - This course consists of 3 parts.

PCSK9i reduces complex coronary disease that requires revascularization

News - Nov. 24, 2020

Pulmonary Arterial Hypertension

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Low-risk profile in pulmonary arterial hypertension patients predicts better survival

Literature - June 6, 2017 - Kylhammar D, et al. - Eur Heart J 2017

siRNA therapy and LDL-C

PCSK9i siRNA therapy for lowering LDL-c levels approved by EC

News - Dec. 14, 2020

PCSK9 siRNA recommended by CHMP for EU approval

News - Oct. 28, 2020

In high-risk primary prevention individuals, RNAi against PCKS9 reduces LDL-c

News - Oct. 6, 2020

Stroke

An overview of the global burden of CVD and risk factors from 1990 to 2019

Literature - Jan. 14, 2021 - Roth GA, et al. - J Am Coll Cardiol. 2020

P2Y12i combined with aspirin superior to aspirin in patients with ipsilateral atherosclerotic stenosis

News - Nov. 24, 2020

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

© 2006 - 2021 pace-cme.org - About